Products Categories
CAS No.: | 492-41-1 |
---|---|
Name: | L-(-)-Ephedrine |
Molecular Structure: | |
|
|
Formula: | C9H13NO |
Molecular Weight: | 151.208 |
Synonyms: | Benzenemethanol,a-(1-aminoethyl)-, [R-(R*,S*)]-;(-)-Norephedrin;(-)-Norephedrine;(-)-Phenylpropanolamine;(-)-erythro-2-Amino-2-methyl-1-phenylethanol;(1R,2S)-(-)-Norephedrine;(1R,2S)-2-Amino-1-phenyl-1-propanol;(1R,2S)-Norephedrine;(1S,2R)-2-Hydroxy-2-phenyl-1-methyl-1-aminoethane;(R,S)-(-)-Norephedrine;L-Norephedrine;NSC 17704;Norephedrine, (-)-;erythro-(1R,2S)-Norephedrine; |
EINECS: | 207-755-7 |
Density: | 1.071 g/cm3 |
Melting Point: | 51-53 °C(lit.) |
Boiling Point: | 288.1 °C at 760 mmHg |
Flash Point: | 128.1 °C |
Appearance: | white powder |
Hazard Symbols: |
![]() |
Risk Codes: | 22-36/37/38 |
Safety: | 26 |
PSA: | 46.25000 |
LogP: | 1.76750 |
Reported in EPA TSCA Inventory.
The L-(-)-Ephedrine is an organic compound with the formula C9H13NO. The IUPAC name of this chemical is (1R,2S)-2-amino-1-phenylpropan-1-ol. With the CAS registry number 492-41-1, it is also named as (-)-erythro-2-Amino-2-methyl-1-phenylethanol. The product's classification codes are Drug / Therapeutic Agent; Human Data. Besides, it is a white powder, which should be stored in dry and well-ventilated place at temperature of 2 - 8 °C.
Physical properties about L-(-)-Ephedrine are: (1)ACD/LogP: 0.81; (2)ACD/LogD (pH 5.5): -2.21; (3)ACD/LogD (pH 7.4): -1.07; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 2; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 4; (11)Polar Surface Area: 12.47 Å2; (12)Index of Refraction: 1.557; (13)Molar Refractivity: 45.46 cm3; (14)Molar Volume: 141 cm3; (15)Polarizability: 18.02×10-24cm3; (16)Surface Tension: 45 dyne/cm; (17)Density: 1.071 g/cm3; (18)Flash Point: 128.1 °C; (19)Enthalpy of Vaporization: 55.7 kJ/mol; (20)Boiling Point: 288.1 °C at 760 mmHg; (21)Vapour Pressure: 0.0011 mmHg at 25°C.
Uses of L-(-)-Ephedrine: it can be used to produce (4R,5S)-(+)-4-methyl-5-phenyloxazolidin-2-one by heating. It will need reagent potassium carbonate and solvent toluene with reaction temperature of 130 °C. The yield is about 80%.
When you are using this chemical, please be cautious about it as the following:
It is harmful if swallowed. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Besides, this chemical is irritating to eyes, respiratory system and skin. When you are using it, wear suitable gloves and eye/face protection.
You can still convert the following datas into molecular structure:
(1)SMILES: O[C@H](c1ccccc1)[C@@H](N)C
(2)InChI: InChI=1/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m0/s1
(3)InChIKey: DLNKOYKMWOXYQA-CBAPKCEABA
(4)Std. InChI: InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m0/s1
(5)Std. InChIKey: DLNKOYKMWOXYQA-CBAPKCEASA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 2500ug/kg (2.5mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: HEADACHE | American Journal of Diseases of Children. Vol. 138, Pg. 683, 1984. |
human | TDLo | oral | 714ug/kg (0.714mg/kg) | VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION | Lancet. Vol. 1, Pg. 60, 1980. |
man | TDLo | oral | 1071ug/kg/1D- (1.071mg/kg) | BEHAVIORAL: WAKEFULNESS BEHAVIORAL: EUPHORIA BEHAVIORAL: TOXIC PSYCHOSIS | Human & Experimental Toxicology. Vol. 11, Pg. 295, 1992. |
mouse | LD50 | intraperitoneal | 200mg/kg (200mg/kg) | National Technical Information Service. Vol. AD277-689, | |
mouse | LD50 | oral | 1060mg/kg (1060mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Bollettino Chimico Farmaceutico. Vol. 109, Pg. 132, 1970. |
mouse | LD50 | subcutaneous | 124mg/kg (124mg/kg) | Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 4, Pg. 139, 1945. | |
mouse | LDLo | intravenous | 114mg/kg (114mg/kg) | Compilation of LD50 Values of New Drugs. | |
mouse | LDLo | unreported | 700mg/kg (700mg/kg) | AUTONOMIC NERVOUS SYSTEM: SYMPATHOMIMETIC | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 153, Pg. 161, 1930. |
rabbit | LDLo | intravenous | 75mg/kg (75mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 36, Pg. 363, 1929. | |
rat | LD50 | oral | 1538mg/kg (1538mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Bollettino Chimico Farmaceutico. Vol. 109, Pg. 132, 1970. |
rat | LDLo | intraperitoneal | 60mg/kg (60mg/kg) | BEHAVIORAL: EXCITEMENT | Toxicology and Applied Pharmacology. Vol. 22, Pg. 138, 1972. |
women | LDLo | oral | 8mg/kg (8mg/kg) | BEHAVIORAL: SLEEP LUNGS, THORAX, OR RESPIRATION: CHRONIC PULMONARY EDEMA CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | British Medical Journal. Vol. 289, Pg. 591, 1984. |
women | TDLo | oral | 500ug/kg (0.5mg/kg) | BEHAVIORAL: HEADACHE | Neurology. Vol. 36, Pg. 593, 1986. |
women | TDLo | oral | 45mg/kg/30D-I (45mg/kg) | CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION | Annals of Emergency Medicine. Vol. 28, Pg. 359, 1996. |